PBCTRAN

Primary Biliary Cirrhosis-Translating genetic discovery into patient benefit

Coordinatore	THE UNIVERSITY OF BIRMINGHAM    more  Organization address address: Edgbaston city: BIRMINGHAM postcode: B15 2TT contact info Titolo: Ms. Nome: May Cognome: Chung Email: send email Telefono: 4412140000000 Fax: 441214000000
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-CIG
Funding Scheme	MC-CIG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-08-01   -   2017-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF BIRMINGHAM  Organization address address: Edgbaston city: BIRMINGHAM postcode: B15 2TT contact info Titolo: Ms. Nome: May Cognome: Chung Email: send email Telefono: 4412140000000 Fax: 441214000000	UK (BIRMINGHAM)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Primary biliary cirrhosis (PBC) is the most prevalent of adult autoimmune liver diseases, seen in both genders and all ethnicities, but remains without rational treatment. Its immune mediated liver injury is driven by interacting innate, humoral and cellular pathways, on a strong background of genetic and environmental risk. Improved treatment is a priority for patients but is hindered by a) complexity inherent to composite genetic and environmental risks; b) inadequate understanding of molecular pathways linking gene signatures to disease and c) challenges associated with personalising and stratifying treatment. We seek to capture the unique and globally recognised strengths of our autoimmune liver disease research programme in Birmingham, to translate our high impact novel genetic risk associations in PBC, to better understanding of pathogenesis, and thereby develop stratified medicine approaches to effective clinical markers and treatment. We will define and profile a cohort of patients with PBC at a molecular level over time; develop rational targets for treatment by laboratory interrogation of the immunoregulatory pathways identified by our own genetic studies; and over the coming years change treatment perspective by bridging biophenotype to clinical practice, utilising novel biomarkers for monitoring and predicting outcome, as well as facilitating targeted personalised treatments.'